Anti-HBV agents derived from botanical origin.

摘要: There are 350,000 hepatitis B virus (HBV) carriers all over the world. Chronic HBV infection is at a high risk of developing liver cirrhosis and hepatocelluar carcinoma (HCC), heavily threatened people's health. Two kinds drugs approved by FDA for anti-HBV therapy immunomodulators (interferon α, pegylated-interferon α) nucleos(t)ide analogues (lamivudine, adefovir dipivoxil, entecavir, telbivudine, tenofovir disoproxil fumarate). These have been proved to be far from being satisfactory due their low specificity, side effects, rate drug resistance. an urgent need discover develop novel effective drugs. With vast resources, various structures, diverse biological activities action mechanisms, as well abundant clinical experiences, botanical agents become promising source finding new This review summarizes recent research development derived origin on sources active components, inhibitory effects possible toxicities, targets also addresses advantages existing shortcomings in inhibitors. information may not only broaden knowledge therapy, offer alternative or substitutive CHB patients, but provides considerable safe